A Phase I/II Trial of HER2 Vaccine-Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2-Overexpressing Breast Cancer.

Disis, Mary L; Dang, Yushe; Coveler, Andrew L; Childs, Jennifer S; Higgins, Doreen M; Liu, Ying; Zhou, Jing; Mackay, Sean; Salazar, Lupe G

Disis, Mary L; Dang, Yushe; Coveler, Andrew L; Childs, Jennifer S; Higgins, Doreen M; Liu, Ying; Zhou, Jing; Mackay, Sean; Salazar, Lupe G.

Afiliação

Disis ML; UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Dang Y; UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Coveler AL; UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Childs JS; UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Higgins DM; UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Liu Y; UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.
Zhou J; IsoPlexis Corporation, Branford, Connecticut.
Mackay S; IsoPlexis Corporation, Branford, Connecticut.
Salazar LG; UW Medicine Cancer Vaccine Institute, University of Washington, Seattle, Washington.

Clin Cancer Res ; 29(17): 3362-3371, 2023 09 01.

Article em En | MEDLINE | ID: mdl-37093223

Assuntos

Neoplasias da Mama; Vacinas Anticâncer; Humanos; Feminino; Neoplasias da Mama/patologia; Linfócitos T/imunologia; Vacinas Anticâncer/imunologia; Antígenos de Neoplasias/imunologia; Epitopos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Vacinas Anticâncer Tipo de estudo: Clinical_trials Limite: Female / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google